TScan Therapeutics, Inc.: CEO MacBeath Gavin received 1,000,000 shares

What happened

• MacBeath Gavin, chief executive officer, received 1,000,000 restricted stock units (transaction code A) on Oct 1, 2026. The filing shows an acquisition price of $0.00, total $0.00.

Key details

• Transaction date and price: Oct 1, 2026; $0.00 per share; total $0.00.
• Filing date and reporting period: filed Oct 2, 2026; period of report Oct 1, 2026.
• Shares owned after the transaction: not reported in the Form 4.
• Footnote F1: 25% of the RSUs vest on Sep 30, 2028; the remaining 75% vest on the earlier of (i) reporting of completion of the pivotal trial of TSC-101, or (ii) Sep 30, 2030, subject to continued service and the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan and the applicable award agreement.
• Transaction code: A (award/grant).

Why it may matter

• This was an award/grant of RSUs, not a market purchase or sale.
• A filing does not show why the insider traded or why the company acted.